A 26-week Single Site, Randomized, Double-blind, Active-controlled, Parallel Group, Human PoC Study to Evaluate Superiority of RK-01, Valsartan Plus Celecoxib Addon to Metformin Versus Metformin Alone in Type 2 Diabetes Patients
Status: Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs Celecoxib (Primary) ; Metformin (Primary) ; Valsartan (Primary)
- Indications Type 2 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Acronyms RESILIENCE
- Sponsors ARKAY Therapeutics
- 07 Oct 2019 Planned End Date changed from 31 Aug 2021 to 31 Jan 2022.
- 07 Oct 2019 Planned primary completion date changed from 31 May 2021 to 30 Nov 2021.
- 07 Oct 2019 Planned initiation date changed from 5 Aug 2019 to 5 Aug 2020.